Filter and sort all 500 stocks
Today's biggest gainers and losers
Visual sector performance
Supernus to Combine with Indivior To Form CNS Biopharmaceutical Leader with Potential $2 Billion in Revenue
Supernus, Indivior merge to strengthen neuroscience drug portfolio